$5.74 Billion in Sales Expected for Gilead Sciences, Inc. (NASDAQ:GILD) This Quarter

Brokerages predict that Gilead Sciences, Inc. (NASDAQ:GILD) will post $5.74 billion in sales for the current quarter, according to Zacks. Seven analysts have made estimates for Gilead Sciences’ earnings, with the highest sales estimate coming in at $6.00 billion and the lowest estimate coming in at $5.61 billion. Gilead Sciences reported sales of $5.80 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 1%. The business is expected to announce its next quarterly earnings results on Monday, February 3rd.

According to Zacks, analysts expect that Gilead Sciences will report full-year sales of $22.29 billion for the current year, with estimates ranging from $22.05 billion to $22.57 billion. For the next fiscal year, analysts expect that the business will post sales of $22.44 billion, with estimates ranging from $20.51 billion to $23.50 billion. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Gilead Sciences.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.01. The company had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.61 billion. Gilead Sciences had a net margin of 12.04% and a return on equity of 37.50%. The firm’s revenue was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.84 earnings per share.

A number of equities analysts recently issued reports on the stock. BMO Capital Markets dropped their price objective on shares of Gilead Sciences from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. Guggenheim set a $86.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Friday, October 25th. Oppenheimer dropped their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Finally, Citigroup set a $78.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $78.87.

In other news, Director Olsen Per Wold sold 4,908 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $63.91, for a total transaction of $313,670.28. Following the sale, the director now owns 102,762 shares in the company, valued at $6,567,519.42. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Brett A. Pletcher sold 608 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $64.35, for a total transaction of $39,124.80. Following the sale, the executive vice president now owns 27,198 shares in the company, valued at approximately $1,750,191.30. The disclosure for this sale can be found here. Insiders have sold 17,288 shares of company stock worth $1,108,682 in the last ninety days. Insiders own 0.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Advisors Preferred LLC bought a new stake in Gilead Sciences in the second quarter worth $26,000. First Financial Corp IN increased its position in Gilead Sciences by 286.4% in the third quarter. First Financial Corp IN now owns 541 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 401 shares during the last quarter. Legacy Advisors LLC bought a new stake in Gilead Sciences in the second quarter worth $37,000. Venturi Wealth Management LLC bought a new stake in Gilead Sciences in the third quarter worth $40,000. Finally, Evolution Wealth Advisors LLC bought a new stake in Gilead Sciences in the second quarter worth $46,000. Hedge funds and other institutional investors own 80.03% of the company’s stock.

GILD opened at $63.33 on Thursday. The company has a current ratio of 2.96, a quick ratio of 2.87 and a debt-to-equity ratio of 1.11. The company has a market cap of $82.72 billion, a price-to-earnings ratio of 10.30, a PEG ratio of 3.47 and a beta of 1.09. The company’s 50 day moving average is $64.02 and its 200 day moving average is $65.29. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $72.90.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 3.98%. The ex-dividend date of this dividend is Thursday, December 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Recommended Story: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.